A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers say the drug ...

Adults with Ph+ CML in the CP or AP, who had imatinib resistance or intolerance and had also failed to respond to dasatinib therapy, received oral nilotinib at a starting dose of 400 mg twice daily on ...

The chronic myeloid leukemia drug nilotinib (Tasigna) improved biomarkers and cognitive outcomes in people with dementia with Lewy bodies (DLB), a small phase II trial showed. In a study of 43 DLB ...

June 21, 2010 (UPDATED July 29, 2010) — The US Food and Drug Administration (FDA) has approved nilotinib (Tasigna, Novartis) as a first-line treatment of chronic-phase Philadelphia chromosome-positive ...

Discover comprehensive details about Nilotinib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

Patients with chronic myeloid leukemia (CML) who have a sustained deep molecular response can maintain treatment-free remission for at least 48 weeks after using second-line nilotinib, according to a ...

A leukemia drug may have cleared another hurdle as a potential treatment for Parkinson's disease. But critics say it's still not clear whether the drug, nilotinib (brand name Tasigna), is truly safe ...

Phase II trial of nilotinib as third-line therapy for gastrointestinal stromal tumor (GIST) patients in Japan. Background: Nilotinib, a novel tyrosine kinase inhibitor (TKI), has been suggested to be ...

WESTON, Fla., May 27, 2025 /PRNewswire/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Apotex Inc.

WASHINGTON - A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer's disease finds that it is safe and well-tolerated, and researchers ...

Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more ...